Aceragen, Inc.

NasdaqCM:ACGN Stock Report

Market Cap: US$3.2m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Aceragen Dividends and Buybacks

Dividend criteria checks 0/6

Aceragen does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-4.3%

Buyback Yield

Total Shareholder Yield-4.3%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Seeking Alpha Sep 28

Idera Pharmaceuticals completes acquisition of Aceragen

Idera Pharmaceuticals (NASDAQ:IDRA) has completed the acquisition of privately-held biotechnology company Aceragen in a stock-for-stock transaction. The acquisition, not subject to the approval of Idera stockholders, was unanimously approved by the board of both the companies. The combined cash of the two companies is expected help in funding the advancement of Aceragen's pipeline through 2023. Idera's former CEO, Vincent Milano, has been named board chair. Aceragen's former CEO, John Taylor, succeeds Milano. Additionally, Aceragen's former chief medical officer, Carl Kraus, will serve in that role for Idera. Also, Aceragen's former COO, Daniel Salain, will serve in that role for Idera. And, Andy Jordan, Aceragen's former CFO has been appointed chief strategy officer for Idera. IDRA shares were trading +19.85% post-market. Source: Press Release
Analysis Article Aug 24

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article May 11

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article Mar 07

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Jan 31

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

With the business potentially at an important milestone, we thought we'd take a closer look at Idera Pharmaceuticals...
Analysis Article Dec 27

Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

If you want to know who really controls Idera Pharmaceuticals, Inc. ( NASDAQ:IDRA ), then you'll have to look at the...
Analysis Article Dec 27

Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

We'd be surprised if Idera Pharmaceuticals, Inc. ( NASDAQ:IDRA ) shareholders haven't noticed that the President...
Analysis Article Nov 25

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, Idera Pharmaceuticals...

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ACGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACGN's dividend payments have been increasing.


Dividend Yield vs Market

Aceragen Dividend Yield vs Market
How does ACGN dividend yield compare to the market?
SegmentDividend Yield
Company (ACGN)n/a
Market Bottom 25% (US)1.3%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.3%
Analyst forecast (ACGN) (up to 3 years)n/a

Notable Dividend: Unable to evaluate ACGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ACGN has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/08/23 16:29
End of Day Share Price 2023/08/21 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aceragen, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael UlzBaird
Michael KingCitizens JMP Securities, LLC
Matthew BannonJ.P. Morgan